Vertex OKd for Expanded Use of CASGEVY® for Ages 2 Years and Older With Sickle Cell

 - First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -

- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -

- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom -

https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment